Addressing an Unmet Medical Need in Urothelial Carcinoma
Christopher J. Hoimes, DO, discusses an unmet medical need in the population of patients with urothelial carcinoma.
Related Articles
Phase 2 Study Reveals Encouraging Results for I-DXd in ES-SCLC
Ifinatamab deruxtecan, a novel antibody-drug conjugate, returned promising response rates at both dose levels evaluated among patients with small cell lung cancer.
FDA Grants Orphan Drug Designation to ABD-147 in Neuroendocrine Carcinoma
The next-generation radiopharmaceutical ABD-147 was previously granted FDA fast track designation in extensive-stage small cell lung cancer.
Firmonertinib Demonstrates Response in NSCLC With EGFR PACC Mutation
Firmonertinib showed efficacy and safety in patients with EGFR PACC-mutated non–small cell lung cancer.
Ensuring AI Accuracy in Cancer Care
Anil Parwani, MD, PhD, addresses potential biases or limitations in the artificial intelligence algorithm used at his institution.
Durvalumab Combo Maintains PFS Benefit in Ovarian Cancer
The combination of durvalumab, chemotherapy, and bevacizumab, followed by maintenance with olaparib, durvalumab, and bevacizumab, improved progression-free survival in newly diagnosed advanced ovarian cancer.
NCCN Guidelines Add Denileukin Diftitox for CTCL Treatment
Denileukin diftitox, an IL-2-receptor-directed cytotoxin, has been added to the NCCN guidelines for the treatment of adult patients with cutaneous T-cell lymphoma.
Mauro on the Future of CML Treatment
Michael J. Mauro, MD, provides a summary of a presentation at the 2024 Society of Hematologic Oncology Annual Meeting on the recent advancements in CML…
Greater Use of Histologic-Based Therapy, Imaging, and MRD Testing Improves Outcomes in PTCL
While challenges exist in treating peripheral T-cell lymphoma, ongoing research is developing more effective therapies.
Quality of Life Considered When Starting Treatment in MDS
Mikkael A. Sekeres MD, MS, discusses when he decides to start therapy for anemia in patients with low-risk myelodysplastic syndromes.
VMT01 Earns FDA Fast Track Designation in MC1R-Positive Melanoma
The novel agent VMT01 is designed to target and deliver 212Pb to MC1R-expressing tumors like metastatic melanoma.